A Phase I, Randomized, Double blinded, Adaptive, Single and Multiple Ascending Dose Study of the Safety and Tolerability of NPI 001 Solution in Healthy Subjects

Trial Profile

A Phase I, Randomized, Double blinded, Adaptive, Single and Multiple Ascending Dose Study of the Safety and Tolerability of NPI 001 Solution in Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs N-acetylcysteine-amide (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions
  • Sponsors Nacuity Pharmaceuticals
  • Most Recent Events

    • 24 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top